May. 6 at 2:30 PM
$LEXX At a
$17M market cap, Lexaria is priced for failure despite hitting every scientific milestone.
For a platform company with FDA-cleared hypertension tech and a fully-funded GLP-1 program that mimics Wegovy’s delivery, the valuation is disconnected from reality.
If Study #7 hits steady-state PK with better safety, you're looking at a
$50M-
$100M baseline "Option to License" floor.
This is a "loaded gun" setup—the boardroom is full, the tech is scaled, and the market is sleeping on the Q4 invoice.
$LLY $NVO $PFE
#GLP1
